Last reviewed · How we verify
NCT05307991
Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe
trial testing PrEP in HIV Infections in 249 participants. Completed in 1 August 2023.
1 August 2023
Quick facts
| Lead sponsor | University of North Carolina, Chapel Hill |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 249 |
| Start date | 9 March 2022 |
| Primary completion | 1 August 2023 |
| Estimated completion | 1 August 2023 |
| Sites | 1 location across Malawi |
Drugs / interventions tested
- PrEP — full drug profile →
- STI testing
- Assisted partner notification
- Acute HIV testing
Conditions studied
- HIV Infections — all drugs for HIV Infections →
- Sexually Transmitted Diseases — all drugs for Sexually Transmitted Diseases →
- Blood-Borne Infections — all drugs for Blood-Borne Infections →
- Communicable Disease — all drugs for Communicable Disease →
Sponsor
University of North Carolina, Chapel Hill
Who can join
15 and older, any sex, with HIV Infections or Sexually Transmitted Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective cohort study evaluating acceptability, feasibility, and effectiveness of integrating HIV pre-exposure prophylaxis (PrEP) into a sexually transmitted infection (STI) clinic alongside assisted partner notification and etiologic STI testing in Lilongwe, Malawi.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Integrating Enhanced HIV Pre-exposure Prophylaxis Into a Sexually Transmitted Infection Clinic in Lilongwe: Protocol for a Prospective Cohort Study.
Rutstein SE, Matoga M, Chen JS, Mathiya E, et al · · 2022 · cited 4× · PMID 36469400 · DOI 10.2196/37395 -
Assisted partner notification as a strategy to enhance Pre-Exposure Prophylaxis (PrEP) screening and uptake - results from a prospective cohort study in Lilongwe, Malawi.
Munthali T, Masano A, Chen JS, Kumwenda W, et al · · 2025 · PMID 40604850 · DOI 10.1186/s12913-025-13038-4 -
High Incidence of Curable Sexually Transmitted Infections Among Persons Accessing Oral Preexposure Prophylaxis at an Integrated Sexually Transmitted Infection/Preexposure Prophylaxis Clinic in Lilongwe, Malawi.
Rutstein SE, Chen JS, Jere E, Limarzi-Klyn L, et al · · 2025 · PMID 40261957 · DOI 10.1097/olq.0000000000002170
Verify or expand the search:
- PubMed search for NCT05307991
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PrEP
Trials testing the same drug.
- NCT06898112 — Mixed-methods Protocol for the WiSSPr Study · completed
- NCT05159531 — Virtual PrEP: Rendering PrEP Delivery More Efficient · Phase 4 · terminated
- NCT05746065 — A Cohort for Evaluation of Open-label PrEP Use and PreP Preferences Among African Women · completed
- NCT04782180 — PrEP at a Syringe Services Program · Phase 4 · completed
- NCT04666792 — PrEParing Family Planning Clinics to Streamline Integration of HIV Prevention Services for Young Women in Kenya · Phase 4 · completed
Other recruiting trials for HIV Infections
Currently open trials in the same condition.
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
- NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
- NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
- NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting
Other University of North Carolina, Chapel Hill trials
Trials by the same sponsor.
- NCT06841913 — Woodsmoke Exposure, Influenza Infection, and Nasal Immunity · Phase 4 · suspended
- NCT07383428 — The INICIO-Guatemala Study · NA · not yet recruiting
- NCT07528443 — Ultraprocessed Foods in Colombia · NA · not yet recruiting
- NCT07507370 — CARED : A Novel Rapid Treatment Paradigm for Depression · NA · not yet recruiting
- NCT07534254 — Piloting a Generative Artificial Intelligence Chatbot in a Mobile Weight Loss Program · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05307991 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of North Carolina, Chapel Hill
- Last refreshed: 5 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05307991.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing